UNSPSC 51334309: Chlorprothixene hydrochloride

This classification denotes an antipsychotic agent with the molecular formula C18H18ClNS.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 268KCR965N, chemically known as 1-propanamine, 3-(2-chloro-9h-thioxanthen-9-ylidene)-n,n-dimethyl-, (z)- but more generally known as chlorprothixene hydrochloride, which bears US NIH Compound Identifier 667466. European Medicines Agency schedules Chlorprothixene hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01257MIG.

Most nations, for tariff and trade purposes, schedule chlorprothixene hydrochloride under HS 29349910 and SITC 51579. As of Q4 2014, CHLORPROTHIXENE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. SMILES: CN(C)CC/C=C\1/C2CCCCC2SC3C1CC(CC3)CL.CL.

UNSPSC 51334309 Chlorprothixene hydrochloride (Commodity) appears in state and local procurement records primarily through misclassification; the recent solicitations tagged to this code do not align with procurement of the specific antipsychotic pharmaceutical. The most recent opportunities actually solicit naloxone and drug deactivation systems, direct-to-manufacturer prescription programs, and generic multi-source pharmaceuticals and OTC products — none of which are chlorprothixene hydrochloride. State and local health agencies, particularly county health departments and state health and human services commissions, do procure controlled pharmaceuticals and psychotropic drugs for community health, institutional care, and emergency response programs, but the available record does not show active demand for chlorprothixene hydrochloride specifically. Issuing bodies in the sample include county governments (Seminole County, Florida), state health authorities (Texas Health and Human Services Commission), and cooperative purchasing alliances serving multiple state and local jurisdictions (Minnesota Multistate Cooperative Purchasing Alliance, or MMCAP).

The geographic spread evident in recent opportunities spans Florida, Texas, and Minnesota-administered cooperatives that include participating states. However, none of these opportunities substantively address chlorprothixene hydrochloride procurement. The Seminole County IFB (IFB60459723LAS, due July 26, 2023) sought naloxone and drug deactivation systems on an annual basis; the Texas HHS RFI (HHS0017013, posted April 3, 2026) explored direct-to-manufacturer prescription program structures without naming specific pharmaceuticals; and MMCAP's RFP (S1070000015802, due March 26, 2026) targeted generic multi-source pharmaceuticals and OTC products through authorized wholesalers. The code shows little relevant recent activity for chlorprothixene hydrochloride specifically and does not support a pursue decision for vendors specializing in this compound.